Avoid common mistakes on your manuscript.
Past
For patients with pancreatic adenocarcinoma (PDAC), surgery followed by multiagent chemotherapy is the most effective treatment.1,2 Because many patients are unable to complete total (6 months) adjuvant chemotherapy, neoadjuvant therapy has emerged as an important strategy for all surgical stages: resectable, borderline-resectable, and locally advanced PDAC.2 Also, there is growing interest in total neoadjuvant therapy (TNT) combining chemotherapy and radiation therapy.3 However, the optimal duration of neoadjuvant treatment and the role of radiation therapy remain undefined.
Present
Our institutional practice to use long-duration neoadjuvant chemotherapy started for patients with borderline resectable and locally advanced PDAC, and after favorable results, extended to those with resectable disease.4 The use of long-duration therapy (median cycles: FOLFIRINOX = 10; gemcitabine-based = 7) is unique.5 Some might even consider this TNT consisting of chemotherapy only. Most (85%) patients received FOLFIRINOX without radiation therapy, and the R0 resection rate was 76%. The median OS was 41 months—the same for all surgical stages.
Future
Although it was not our official policy, patients with all surgical stages generally received neoadjuvant chemotherapy for 6 months unless shortened or stopped because of adverse effects (~25% of patients).5 With FOLFIRINOX, stable disease was expected after four cycles, and for approximately half of patients who demonstrated tumor shrinkage, smaller tumors were not usually seen until after eight cycles. For patients with borderline resectable and locally advanced disease that persisted radiographically after neoadjuvant chemotherapy, radiation therapy was used selectively if the CA 19-9 remained elevated. FDG-PET/CT was not regularly used for Lewis antigen-negative patients to guide therapy decisions.
Given these favorable results, future studies of TNT for all stages of PDAC might consider including a systemic therapy alone arm.5 Our findings also reinforce that PDAC is a systemic disease requiring good systemic and surgical therapy for favorable outcomes.
References
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20(5):318–37. https://doi.org/10.1038/s41571-023-00746-1.
De Simoni O, Scarpa M, Soldà C, et al. Could total neoadjuvant therapy followed by surgical resection be the new standard of care in pancreatic cancer? A systematic review and meta-analysis. J Clin Med. 2022;11(3):812. https://doi.org/10.3390/jcm11030812.
Kim SS, Nakakura EK, Wang ZJ, et al. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016;114(5):587–96. https://doi.org/10.1002/jso.24375.
Miller PD, Romero-Hernandez F, Calthorpe L, et al. Long-duration neoadjuvant therapy with FOLFIRINOX yields favorable outcomes for patients who undergo surgery for pancreatic cancer. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15579-0.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors have no conflicts of interest or funding to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article refers to: Miller PD, Romero-Hernandez F, Calthorpe L, et al. Long-duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Annals Surgical Oncology. (2024). https://doi.org/10.1245/s10434-024-15579-0.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Miller, P.N., Nakakura, E.K. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15660-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1245/s10434-024-15660-8